Drug for mood disorder

Quinn Karylle Fuentes · 28問 · 2年前

通報

問題一覧

Major depressive disorder/ clinical depression

Depression.

Abnormally elevated arousal energy level

Mania

Milder form of mania. Mood state or energy level that is elevated above normal, but not so extreme as to cause impairment

Hypomania

persistent depressive disorder

Dysthymia

Bipolar formerly known as

Manic depressive.

Moods which cycle between mania and depression known

Bipolar disorder

Cycle between elation and dysthymia

Cyclothymia

Depression also know as Also known as?

Major Depressive Disorder

Research suggests that depression is caused by a combination of

genetic, biological, environmental, psychological factors.

Depression is associated with the loss of neurotrophic support from nerve growth factors such as BDN

Neurotropic hypothesis

Suggests that depression is related to a deficiency in the amount or function of cortical and limbic 5-HT, NE and dopamine

Mao hypothesis

Increase in cortisol level (Cushing’s disease), Thyroid desregulation and Sex steroids (estrogen and testosterone deficiency)

Abnormalities in Hormone

The most common antidepressant in clinical use. More modern and safe antidepressant

SSRI

1st drug available in 1988

Fluoxetine

CYP3A4

Fluvoxamine

CYP2D6

Fluoxetine, Paroxetine

Drug for bulimia nervosa

Fluoxetine

Drug for Premenstrual Dysphoric disorder-

Sertraline (Zoloft), Fluoxetine (Fluoxentine)

Used for Pain disorders (neuropathies, fibromyalgia

Milnacipran

Binds and inhibits both the SERT and NET

SNRI

with hepatic toxicity in patients with a history of liver damage.

Duloxetine

Originally developed as antipsychotics (1949), but were found to have no effect in this indication

TCA

blockade of re-uptake of noradrenaline (NA) and serotonin (5-HT)

TCA

blockade of H1-receptor, α-receptors, Mreceptors

TCA

in TCA it inactive metabolites excreted in the urine

Glucuronidation

What isbthe treatment for seizure

Diazepam

Sedation, drowsiness, difficulty in concentration - H1-blockade

Amitriptyline

is found in the liver, gastrointestinal tract, and placenta. generally metabolizes tyramine, norepinephrine (NE), serotonin (5-HT), and dopamine (DA)

MAO-A

is mostly found in blood platelets. ⏤ mainly metabolizes dopamine (DA)

MAO-B

The first compounds (iproniazide derivatives) - originally developed as antimycobacterial drugs by chemical modification of isoniazid molecule (1950s).

MAO inhibitors

when given to normal non-depressed subjects they increase a motor activity and cause euphoria + excitements ⇒ risk of abuse!

MAO inhibitors

Irreversible non-selective (MAOA and MAOB) inhibitors

Hydrazines

long lasting inhibition (up to 1-2 weeks) despite of the elimination rate of a drug

Hydrazine

Reversible Inhibitors of MAO-A (RIMA)

Non-hydrazines

Reversible inhibitors of MAO-B (e.g. selegiline) are used in the treatment of Parkinson's disease

MAO-B selective.

plant chemical obtained from St. John’s Wort ((Hypericum perforatum)

Hyperforin

A. MAOIs + Tyramine rich food can lead to what Disease

Hypertensive crisis

What is the treatment for hypertensive crisis

Sodium nitroprusside.

MAOIs + SSRI/ TCA/ opioids can lead to what disease

Serotonin syndrome

What is the Drug of choice in serotonin syndrome

Cyproheptadine

MAOIs + BZD/ Alcohol/ Antihistamine can lead to

prolong and profound the effect, increase sedation

Used in depression with significant anxiety and sleep disturbances

5HT2A ANTAGONISTS

5HT2A antagonist what receptors

Histamine 1, Alpha 1, Alpha 2

Prolonged and painful penile erection

Trazodone

If 5HT2A ANTAGONISTS has a side effects of hepatotoxicity what is the possible drug of choice should be given

Nefazodone

Noradrenaline and Dopamine Reuptake Inhibitors (NDRI)

Bupropion

severe depression + smoking cessation treatment

Bupropion

Noradrenergic Specific Serotonergic antidepressant ⏤Also inhibits presynaptic α2-adrenergic receptors, which leads to increased central concentrations of norepinephrine and 5-HT.

Mirtazapine

N -methylated metabolite of loxapine, an older antipsychotic drug.

Amoxapine

associated with a parkinsonian syndrome due to its D2 -blocking action

Amoxapine

the neurotransmitter levels fluctuate and may be similar or reversed, depending on the patient’s current clinical presentation.

Bipolar disorder

manic or mixed episodes May have other mood episodes

Bipolar 1

1 + major depressive episodes and 1 + hypomanic episodes Never manic or mixed episode

Bipolar 2

Cycle between elation and dysthymia diagnosed when the depressive and hypomanic symptoms persist for 2 years.

Cyclothymia

ideations or expansive self-esteem

Grandiose

high excess involvement in pleasurable activities

Hendonism

Inc. NE, Dec. GABA means

Mania

Dec. NE

Depression

A mixed episode is the coexistence of manic and depressive symptoms for at least 1 week. This is often referred to as mood incongruent.

Mixed episode

acute agitation associated with mania can prescribe what drug

Benzodizepam, Lorazepam

may be used if parenteral administration is necessary to manage acute agitation.

Haloperidol

Im case such as Severed depression or suicidal ideation what drug of choice should be given

bupropion, paroxetine (Paxil)

First line agents for bipolar

Lithium, Lamotrigine

Maintains the normal balance of calcium and sodium= abnormal level will cause mood fluctuation.

Phospoinositides

lithium + antipsychotics or BZD will lead to

increase the risk of neurotoxicity

lithium + medications that increase 5-HT

Serotonin syndrome

It can be used as monotherapy in bipolar disorder or as an adjunctive therapy with lithium or another mood stabilizer.

Valproic acid (Depakene)

An antiepileptic drug used also in bipolar disorder

Carbamazepine (Tegretol)

It is also used in the management of trigeminal neuralgia

Carbamazepine (Tegretol)

It is also used in the management of trigeminal neuralgia

Carbamazepine (Tegretol)

- reserved for use in bipolar patients with partial or no response to lithium.

Carbamazepine (Tegretol)

An antiseizure that is also used for bipolar- approved for prevention of recurrence

Lamptrigine (lamictal)

Block sodium meditate and GABA

Lamotrigine (Lamictal)

An antiseizure with mood stabilizing activity- adjunctive mood stabilizer.

Gabapentin (Neurontin)

expected to have comparable efficacy in the management of bipolar disorder, with fewer side effects and better tolerability.

Oxcarbazepine (Trileptal)

Patients w/ hematologic diseases- CBZ and VPA comb. is not recommended (T/F)

True

In pregnancy what can possibly cause birth defect

Lithium, VPA, CBZ

Mao inhibitors are drig reserve for?

atypical depression, refractory to other antidepressants

diazepam also used as?

anticonvulsant

Short and intermediate acting drugs used as

Anxiolytic

ultrashort acting drugs used as

pre anesthetic

What is drug of choice in benzodiazepine poisoning

flumazenil

Dopamine metabolis what inhibitor

MAO-B

Mao-b is used in?

Parkinsonism

Cell structure.

Cell structure.

28問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Electrolytes and non electrolytes

Electrolytes and non electrolytes

29問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

POST LAB (EXP 4)

POST LAB (EXP 4)

38問 • 2年前

Density and specific gravity

Density and specific gravity

Quinn Karylle Fuentes · 18問 · 2年前

FORCES OF ATTRACTION

FORCES OF ATTRACTION

18問 • 2年前

Quinn Karylle Fuentes · 63問 · 2年前

Microbial growth

Microbial growth

63問 • 2年前

Quinn Karylle Fuentes · 61問 · 2年前

Introduction.

Introduction.

61問 • 2年前

Quinn Karylle Fuentes · 97問 · 2年前

Microbial control.

Microbial control.

97問 • 2年前

Quinn Karylle Fuentes · 100問 · 2年前

States of matter

States of matter

100問 • 2年前

Quinn Karylle Fuentes · 86問 · 2年前

Introduction.

Introduction.

86問 • 2年前

Quinn Karylle Fuentes · 77問 · 2年前

Drug development.

Drug development.

77問 • 2年前

Quinn Karylle Fuentes · 9問 · 2年前

CGMP

CGMP

9問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Pharmaceutical ingredients.

Pharmaceutical ingredients.

24問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Powdered & granules

Powdered & granules

43問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Capsule.

Capsule.

24問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Tablets.

Tablets.

23問 • 2年前

Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

Calculatiom of dose

Calculatiom of dose

3回閲覧 • 66問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Postlab 5&6

Postlab 5&6

29問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

COLLIGATIVE PROPERTIES.

COLLIGATIVE PROPERTIES.

33問 • 2年前

Quinn Karylle Fuentes · 69問 · 2年前

SEMI SOLID

SEMI SOLID

69問 • 2年前

Quinn Karylle Fuentes · 60問 · 2年前

Basic immunology

Basic immunology

60問 • 2年前

Quinn Karylle Fuentes · 62問 · 2年前

Basic immunology (2)

Basic immunology (2)

62問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

Transdermal

Transdermal

44問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Distribution.

Distribution.

43問 • 2年前

Quinn Karylle Fuentes · 65問 · 2年前

Infectious disease.

Infectious disease.

65問 • 2年前

Quinn Karylle Fuentes · 79問 · 2年前

Infectious diseases (2)

Infectious diseases (2)

79問 • 2年前

Gram positive ( Bacteriology)

Gram positive ( Bacteriology)

All topic. ( Compressed.)

All topic. ( Compressed.)

Quinn Karylle Fuentes · 30問 · 2年前

All topic ( Compressed)

All topic ( Compressed)

30問 • 2年前

Quinn Karylle Fuentes · 13問 · 2年前

All topics (compressed)

All topics (compressed)

13問 • 2年前

Quinn Karylle Fuentes · 28問 · 2年前

Exercise 6 ; Isotonic solution.

Exercise 6 ; Isotonic solution.

28問 • 2年前

Quinn Karylle Fuentes · 16問 · 2年前

Exercise 5 : Buffers.

Exercise 5 : Buffers.

16問 • 2年前

Quinn Karylle Fuentes · 26問 · 2年前

Exercise 7 : Factors affecting solubility.

Exercise 7 : Factors affecting solubility.

26問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Experiment 8: Disintegration.

Experiment 8: Disintegration.

23問 • 2年前

Experiment 9 ; Interfacial phenomenon and surface tension.

Experiment 9 ; Interfacial phenomenon and surface tension.

EXP 9 : Aromatic ammonia spirit.

EXP 9 : Aromatic ammonia spirit.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

Quinn Karylle Fuentes · 20問 · 2年前

EXP 12: ACACIA MUCILAGE

EXP 12: ACACIA MUCILAGE

20問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

EXP13&14 : Starch and Barrium sulfate.

EXP13&14 : Starch and Barrium sulfate.

33問 • 2年前

Quinn Karylle Fuentes · 37問 · 2年前

EXP 15 : Liquid petroleum emulsion 1.0

EXP 15 : Liquid petroleum emulsion 1.0

37問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

EXP 15: Liquid petroleum emulsion 1.1

EXP 15: Liquid petroleum emulsion 1.1

23問 • 2年前

Enterobacteriaceae

Enterobacteriaceae

Quinn Karylle Fuentes · 28問 · 2年前

Enterobacteriaceae.

Enterobacteriaceae.

28問 • 2年前

Quinn Karylle Fuentes · 31問 · 2年前

LIQUID DOSAGE FORM 1.0

LIQUID DOSAGE FORM 1.0

31問 • 2年前

Quinn Karylle Fuentes · 12問 · 2年前

Liquid dosage form

Liquid dosage form

12問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

MICROMERITICS 1.0

MICROMERITICS 1.0

44問 • 2年前

Quinn Karylle Fuentes · 22問 · 2年前

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

22問 • 2年前

Quinn Karylle Fuentes · 40問 · 2年前

EXP 8 : KIRBY-BAUER TECHNIQUE

EXP 8 : KIRBY-BAUER TECHNIQUE

40問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

EXP 9: STAPHYLOCOCCI

EXP 9: STAPHYLOCOCCI

29問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug incompatibilities.

Drug incompatibilities.

41問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug compatibilities.

Drug compatibilities.

41問 • 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

Quinn Karylle Fuentes · 30問 · 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

30問 • 2年前

SUSPENSION.

SUSPENSION.

Quinn Karylle Fuentes · 40問 · 2年前

Colloidal.

Colloidal.

40問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

BACTERIOLOGY 4 (Rickettsia)

BACTERIOLOGY 4 (Rickettsia)

38問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

BACTERIOLOGY.

BACTERIOLOGY.

44問 • 2年前

Quinn Karylle Fuentes · 32問 · 2年前

Emulsion.

Emulsion.

32問 • 2年前

Quinn Karylle Fuentes · 42問 · 2年前

EMULSION

EMULSION

42問 • 2年前

Quinn Karylle Fuentes · 36問 · 2年前

MEDICAL RELATED PROBLEMS.

MEDICAL RELATED PROBLEMS.

36問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

MEDICATION RELATED PROBLEMS.

MEDICATION RELATED PROBLEMS.

33問 • 2年前

Quinn Karylle Fuentes · 30問 · 2年前

Mycology.

Mycology.

30問 • 2年前

Mycology 2.0

Mycology 2.0

Quinn Karylle Fuentes · 15問 · 2年前

15問 • 2年前

Quinn Karylle Fuentes · 25問 · 2年前

ppr

ppr

25問 • 2年前

Quinn Karylle Fuentes · 20問 · 2年前

MEDICAL DEVICES.

MEDICAL DEVICES.

20問 • 2年前

Quinn Karylle Fuentes · 86問 · 2年前

Pharmacokinetics. (1.0)

Pharmacokinetics. (1.0)

86問 • 2年前

Quinn Karylle Fuentes · 100問 · 2年前

Pharmacokinetics (1.1)

Pharmacokinetics (1.1)

100問 • 2年前

Quinn Karylle Fuentes · 19問 · 2年前

Pharmacokinetics (1.2)

Pharmacokinetics (1.2)

19問 • 2年前

Quinn Karylle Fuentes · 17問 · 2年前

Introduction.

Introduction.

17問 • 2年前

Quinn Karylle Fuentes · 76問 · 2年前

Introduction of biochemistry

Introduction of biochemistry

76問 • 2年前

Quinn Karylle Fuentes · 56問 · 2年前

Intro medicanal chemistry.

Intro medicanal chemistry.

56問 • 2年前

Quinn Karylle Fuentes · 75問 · 2年前

Carbohydrates

Carbohydrates

75問 • 2年前

Quinn Karylle Fuentes · 31問 · 2年前

Carbohydrates 1.1

Carbohydrates 1.1

31問 • 2年前

Quinn Karylle Fuentes · 56問 · 2年前

Detect and quality variation.

Detect and quality variation.

56問 • 2年前

Quinn Karylle Fuentes · 98問 · 2年前

INTRODUCTION

INTRODUCTION

98問 • 2年前

Quinn Karylle Fuentes · 15問 · 2年前

lab (1-2)

lab (1-2)

15問 • 2年前

Quinn Karylle Fuentes · 14問 · 2年前

lab 1-2

lab 1-2

14問 • 2年前

Pharmaceutical chemistry.

Pharmaceutical chemistry.

Pharmaceutical chemistry 1.1

Pharmaceutical chemistry 1.1

Quinn Karylle Fuentes · 39問 · 2年前

Unit 3.

Unit 3.

39問 • 2年前

Quinn Karylle Fuentes · 70問 · 2年前

Histamin and kinins

Histamin and kinins

70問 • 2年前

PUD.

PUD.

Quinn Karylle Fuentes · 61問 · 2年前

61問 • 2年前

Quinn Karylle Fuentes · 67問 · 2年前

Lipids.

Lipids.

67問 • 2年前

Quinn Karylle Fuentes · 71問 · 2年前

lipids.

lipids.

71問 • 2年前

Quinn Karylle Fuentes · 93問 · 2年前

LAB ✨

LAB ✨

93問 • 2年前

Quinn Karylle Fuentes · 87問 · 2年前

Drug discovery.

Drug discovery.

87問 • 2年前

Quinn Karylle Fuentes · 13問 · 2年前

disease of lipids.

disease of lipids.

13問 • 2年前

Quinn Karylle Fuentes · 57問 · 2年前

Intro (identify structure)

Intro (identify structure)

57問 • 2年前

Quinn Karylle Fuentes · 98問 · 2年前

Carbohydrates

Carbohydrates

98問 • 2年前

Quinn Karylle Fuentes · 96問 · 2年前

Dynamic.

Dynamic.

96問 • 2年前

Quinn Karylle Fuentes · 32問 · 2年前

Unit 1

Unit 1

32問 • 2年前